CytoSorbents Q1 2024 GAAP EPS $(0.12), Inline, Sales $9.787M Beat $9.785M Estimate
CytoSorbents Q1 2024 GAAP EPS $(0.12), Inline, Sales $9.787M Beat $9.785M Estimate
CytoSorbents 2024年第一季度GAAP每股收益爲0.12美元（0.12美元），直列式，銷售額爲978.7萬美元，超過預期的978.5萬美元
CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 29.41 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $9.787 million which beat the analyst consensus estimate of $9.785 million by 0.02 percent. This is a 3.58 percent increase over sales of $9.449 million the same period last year.
CytoSorbents（納斯達克股票代碼：CTSO）公佈的季度虧損爲每股0.12美元，符合分析師的共識預期。這比去年同期每股虧損0.17美元（0.17美元）增長了29.41％。該公司公佈的季度銷售額爲978.7萬美元，比分析師普遍預期的978.5萬美元高出0.02％。這比去年同期的944.9萬美元的銷售額增長了3.58％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。